OLMA Olema Pharmaceuticals, Inc.
$10.22▼ -4.40%
Healthcare
Other
After hours
$8.76▼ -14.32%
Sep 11, 7:58 PM ET
Volume 895.2K
Avg Volume (10D) 768.9K
Key Metrics & Fundamentals
Market Cap
$894.23M
P/E Ratio
–
Div Yield
–%
52W Range
6.65 - 36.26
% vs 50 MA
-9.41%
% vs 200 MA
-41.70%
RSI-14
41.9
MACD Histogram
+0.0000
Beta (1Y vs SPY)
0.39
Free Cash Flow
-$46.12M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$67.08M
COGS
–
Operating Exp
$67.18M
Operating Income
-$67.18M
EBIT
-$67.18M
Pretax Income
-$63.20M
Net Income
-$63.20M
EPS (Diluted)
-0.61
Price & Volume History
Loading chart…
Recent News
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 2, 2026 8:30 PM
Olema Oncology to Participate in Upcoming Investor Conferences
GlobeNewswire · Aug 31, 2026 8:30 PM
Olema Pharmaceuticals Names Jason O'Byrne CFO
MT Newswires · Aug 13, 2026 12:48 PM
Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer
GlobeNewswire · Aug 13, 2026 11:00 AM
Olema Pharmaceuticals Q2 Loss Widens
MT Newswires · Aug 10, 2026 9:32 PM
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results
GlobeNewswire · Aug 10, 2026 8:01 PM
Does Olema Pharmaceuticals' (OLMA) Broad Russell Growth Inclusion Reveal a Turning Point in Its Investor Story?
Simply Wall St. · Jun 30, 2026 12:07 PM
How Olema Pharmaceuticals (OLMA) Is Adding Pipeline Depth Behind Its Palazestrant Breast Cancer Bet
Insider Monkey · Jun 17, 2026 3:17 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See OLMA's money flow as a full page
Social Sentiment
No Reddit posts found for OLMA.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.